*Please note the Pre-Conference Focus Day has been Cancelled*

8:00 am Registration Opens

8:50 am Chair’s Opening Remarks

  • Nora Disis Professor, Clinical Research Division, Fred Hutch

Optimizing Cancer Vaccine Delivery, Antigen Selection, Identification, & Validation

9:00 am Transcriptional Instability in Prostate Cancer as a Source of Shared Neoantigens


  • Identify a novel instability in cancer wherein cancer cells alter their transcriptional machinery and generate highly recurrent de novo RNA transcripts while maintaining a wild type genome status
  • These aberrant transcription programs result in gene fusions and alternative RNA splicing that could generate long stretches of novel amino acid sequences.
  • Our data supports the hypothesis that these aberrant transcription events generate an unanticipated and reproducible vulnerability that could be exploited for various therapeutic modalities.

9:30 am Sargramostim as a Vaccine Adjuvant

  • Tim Boyd Director of Development , Partner Tx


  • GM-CSF induction of non-lymphoid tissue-resident dendritic cells (DCs) is
    imperative for CD8+ T cell responses, leading to a history of GM-CSF use as an
    adjuvant in numerous vaccines.
  • Studies have reported both increased immune responses and immune
    suppression, depending upon GM-CSF dosage and frequency.
  • Concurrent strategies to suppress immunoregulatory cells may enhance GMCSF-
    mediated DC induction as a strategy to boost adjuvanticity in emerging
    vaccine therapies.

10:00 am Is there a Single “Best” Platform or will it be “Fit to Purpose”?

  • Jeffrey Bockman Executive Vice President of Commercial BioConsulting & Head of Oncology, Lumanity


  • Analysing the advantages, disadvantages and comparisons of the DNA, Peptide, RNA, and Virus-based and other novel vaccine platforms
  • Harmonisation of clinical outcomes and immune correlates
  • Considering if we can we get better at predictive animal models?
  • Questioning what other signals we need to provide to the immune system, either built into the vaccine or given concomitantly (checkpoints, costims, cytokines, innate immunity boosters, etc.

10:30 am Morning Refreshments & Speed Networking

Optimizing Cancer Vaccine Delivery, Combination Therapies, & Antigen Selection Continued

11:15 am Identification and Validation of Neoantigens Resulting from Neo-open Reading Frames

  • Katka Franke Associate Director Immunology, CureVac Netherlands


  •  Combination of the whole genome sequencing with short- and long-RNA sequencing unleashes the full potential of cancer neoantigen discovery
  • Showcasing how these technologies allow identification of neo-open reading frame peptides that represent long and completely foreign stretches of amino acids resulting from frame-shift mutations and genomic rearrangements in tumor tissue
  • Identifying and validating several neo-open reading frame peptides as neoantigens suitable for both off-the-shelf and personalized cancer vaccines

11:45 am Panel Discussion: How can biotechs best leverage partnerships early on in drug development to ensure cancer vaccine success?


  • Assessing the importance of bringing in the right staff from the field
  • Developing the science and the story in early development to attract potential
    partners, when you don’t have clinical data available
  • Attributes of a perfect partnership
  • Types of partnerships (in/out licensing of product, financing of clinical trial,
    providing comparator drug, etc.)
  • Key partnerships crucial at different timepoints
  • Evidence from the field where effective partnerships have resulted in key

12:15 pm Lunch and Networking

1:15 pm Viral Vectored Vaccines Targeting Many Neoantigens elicit effective anti-tumor T cell immunity and response in combination with anti-PD1


  • Nouscom proprietary engineered viral vectors encoding large number of tumor
    neoantigens elicit strong immune response and effectively synergize with
    checkpoint inhibitors (CPI) to eradicate large tumors in preclinical models
  • Effectiveness of vaccination is CD8 mediated and correlates with expansion and
    diversification of the intratumoral T cell repertoire
  • Clinical development in indications with high Tumor Mutational Burden
    responsive to CPI, with an off-the-shelf vaccine targeting 209 shared frameshift
    mutations for treatment of MSI tumors and a personalized vaccine targeting
    up to 60 neoantignes for treatment of NSCLC and melanoma: preliminary
    clinical evidence

1:45 pm Leveraging innate and adaptive mechanisms of anticancer immunity with IV heterologous vaccination


  • SNAPvaxTM is a self-assembling nanoparticle codelivering TLR-7/8a and cancer antigens
  • ChAdOx is an adenovirus that can be programmed to encode cancer antigens and has been demonstrated to be safe and effective for inducing T cell immunity in patients
  • Intravenous heterologous prime boost with SNAPvax and ChAdOx results in improved tumor clearance in preclinical animal models through two distinct mechanisms of action: (i) direct innate activation and reversal of suppressive populations within tumors, and (ii) induction of high magnitude T cells responses that mediate tumor killing.

2:15 pm Vaccines that Selectively Induce Type I T-cell Responses to Tumor Associated Antigens

  • Nora Disis Professor, Clinical Research Division, Fred Hutch


  • Discovery of new molecular targets for cancer immunotherapies
  • Clinical trial data testing HER-2–based cancer vaccines

2:45 pm Altering the Human Prostate Tumor Immune Microenvironment Through Inhibition of Ibrutinib


  • This is the first clinical trial of the BTK inhibitor ibrutinib in prostate cancer
  • Ibrutinib may alter favorably alter the prostate tumor microenvironment by reducing pro-tumor B cells and increasing anti-tumor T cells
  • Inhibition of BTK may also limit tumor cell-intrinsic growth
  • Prostate tissue and peripheral correlative studies will be performed to evaluate the further use of ibrutinib in prostate cance

3:15 pm Chair’s Closing Remarks and Close of Summit